Severe asthma

79
Severe Asthma 20-9-13 Suparat Sirivimonpan, MD.

description

Severe asthma Presented by Suparat Sirivimonpan, MD. 20130920

Transcript of Severe asthma

Page 1: Severe asthma

Severe Asthma20-9-13

Suparat Sirivimonpan, MD.

Page 2: Severe asthma

Topic outline

• Introduction• Epidemiology• Definition• Characteristics• Management• Take home message

Page 3: Severe asthma

Introduction• The prevalence of asthma has continued to

increase significantly

• Fortunately, most patients with asthma can achieve good control of their disease

• A significant proportion of patients with asthma remains symptomatic despite treatment with high-dose ICSs, inhaled LABAs, and, even in some cases, systemic corticosteroids

Bell MC, Busse WW.J Allergy Clin Immunol: In Practice 2013;1:110-21

Page 4: Severe asthma

Introduction• This group has been defined as having severe

asthma, refractory asthma, or treatment-resistant asthma

• Severe asthma remains a major challenge for the clinician because these patients require the greatest degree of health care and experience the most morbidity

Bell MC, Busse WW.J Allergy Clin Immunol: In Practice 2013;1:110-21

Page 5: Severe asthma

Epidemiology

• The Severe Asthma Research Program (SARP) from the National Heart, Lung, and Blood Institute (NHLBI) – 15% of asthmatic patients are in this group

Jarjour NN,et al. Am J Respir Crit Care Med 2012;185:356-62

Page 6: Severe asthma

• intermittent asthma 62.9%• mild persistent asthma 10.5% • moderate persistent asthma 17.6%• severe persistent asthma 9.0%

Respirology 2004;9:373-378

Page 7: Severe asthma

Definition

Page 8: Severe asthma

Definition

• Severe asthma• Difficult-to-treat asthma• Difficult/therapy-resistant asthma• Refractory asthma

Page 9: Severe asthma

Definition• Definitions of “severe asthma” by the WHO

1. Untreated severe asthma

2. Difficult-to-treat severe asthma

3. Treatment-resistant severe asthma - Asthma for which control is not achieved despite the highest level of recommended treatment: refractory asthma and corticosteroid-resistant asthma - Asthma for which control can be maintained only with the highest level of recommended treatment

most challenging

Bousquet J,et al. J Allergy Clin Immunol 2010;126:926-38

Page 10: Severe asthma

• Definitions “Refractory asthma” by ATS workshop , SARP (Severe Asthma Research Program)

ATS. Am J Respir Crit Care Med 2000;162:2341-51.

1/2

2/7

Page 11: Severe asthma

DefinitionDefinitions “difficult/therapy-resistant asthma” • by The European Respiratory Society task force (1999)

• Patients with poorly controlled asthma who require continued requirement for short-acting beta 2-agonists despite delivery of a reasonable dose of inhaled corticosteroids

• Patients may require courses of oral corticosteroids or a regular dose of oral corticosteroids to maintain reasonable control of the disease

• regular follow-up with a respiratory specialist for 6 months

Page 12: Severe asthma

GINA2008

GINA. Eur Respir J 2008;31:143-78.

Page 13: Severe asthma

• definitions of patients with severe asthma focus on

persons who require primarily large doses of ICSs in attempts to achieve

disease control

Page 14: Severe asthma

Characteristics

Page 15: Severe asthma

Adults

Eur Respir J 2003; 22:470-7.

European Network For Understanding Mechanisms Of Severe Asthma

Page 16: Severe asthma

Eur Respir J 2003; 22:470-7.European Network For Understanding Mechanisms Of Severe Asthma

Age 17–65 yrs

Page 17: Severe asthma

Non atopy

• fewer positive reactions in the severe asthma group• no significant differences : Alternaria and Aspergillus fumigatus

Eur Respir J 2003; 22:470-7.

Page 18: Severe asthma

• lower FEV1 values with less reversibility after bronchodilator

Eur Respir J 2003; 22:470-7.

Page 19: Severe asthma

• significantly greater number of neutrophils in their sputum• no difference in the number, or proportion, of eosinophils or other leukocytes

Eur Respir J 2003; 22:470-7.

Page 20: Severe asthma

• significantly greater urinary eosinophil protein X (EPX) and urinary leukotriene E4

Eur Respir J 2003; 22:470-7.

Page 21: Severe asthma

• Persistent symptoms and abnormal lung function, despite high-dose regular use of controller and reliever medications, is accompanied by a component of irreversible airflow obstruction, neutrophilic inflammation, ongoing mediator release and reduced association with atopy.

Eur Respir J 2003; 22:470-7.

Page 22: Severe asthma

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Page 23: Severe asthma

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.similar age and sex distribution

Page 24: Severe asthma

• Symptoms were significantly higher in children with severe versus mild-to-moderate asthma – Composite symptom scores, including cough,

sputum production, chest tightness, wheezing, shortness of breath, and nocturnal awakenings in the 3 months before enrollment

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Page 25: Severe asthma

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Subjects with severe asthma also had lower baseline FEV1 values but showed greater reversibility after bronchodilator administration

No significant correlations were observed between spirometry variables and symptom scores

Page 26: Severe asthma

Bronchoprovocation testing• Mean PC20 was significantly lower in severe asthma

(1.69 ± 2.28 vs 10.24 ± 10.47 mg/mL; P = .010) • remained different between the 2 groups after

controlling for serum IgE and the number of positive skin prick responses (P = .011)

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Page 27: Severe asthma

Allergic sensitization• children with severe asthma had significantly higher serum IgE

(821 ± 1066 vs 301 ± 413 kU/L; P = .002) • more positive skin prick reactions to aeroallergens (mean 5 ± 3 vs

3 ± 3; P = .009), – weed mix (34% vs 6%; P =.023)– Dfarinae (79% vs 50%; P = .039)– Dermatophagoides pteryn (86% vs 56%; P = .024)

• not different with regard to animal dander, tree, or mold sensitization

• The percentage of eosinophils in peripheral blood was not different

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Page 28: Severe asthma

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.(*P < .05)

severe asthma

severe asthma

6-month period of observation

Page 29: Severe asthma

• Children with severe asthma have greater airway obstruction, increased markers of allergic sensitization, increased bronchial hyperresponsiveness to methacholine, and lung hyperexpansion

• Both the obstructive changes in lung function and elevated FENO persist over time despite adjustments in ICS treatment

Fitzpatrick AM,et al.J Allergy Clin Immunol 2006;118:1218-25.

Page 30: Severe asthma

Jenkins HA, et al. Chest 2003;124:1318-24.

Page 31: Severe asthma

Jenkins HA, et al. Chest 2003;124:1318-24.

Page 32: Severe asthma

Jenkins HA, et al. Chest 2003;124:1318-24.

children with severe asthma tended to be more responsive to glucocorticoids in vitro and tended to have less impairment in lung function than adult counterparts

Page 33: Severe asthma

Jarjour NN,et al. Am J Respir Crit Care Med 2012;185:356-62

Page 34: Severe asthma

Management

Page 35: Severe asthma

Management Proposals for the management of severe asthma• Accurate diagnosis (need PEF or spirometry)• Accurate assessment of severity• Assessment and prevention of risk factors• Assessment and control of comorbidities• Appropriate therapy (ICS, SABAs, LABAs), given with an

appropriate drug delivery device• Assessment of control (WHO-PEN, asthma control

questionnaires, symptoms, and so forth)• Ongoing support in self-management and patient education• Well-trained health professionals

Bousquet J,et al. J Allergy Clin Immunol 2010;126:926-38

**WHO Package of Essential Interventions for Noncommunicable Diseases [WHO-PEN]

Page 36: Severe asthma

Bousquet J,et al. J Allergy Clin Immunol 2010;126:926-38

Accurate Dx

radiographic imaging

Page 37: Severe asthma

Comorbidities• Rhinitis• Sinusitis • Gastroesophageal reflux disease • Allergic bronchopulmonary aspergillosis (ABPA),

or other allergic mycoses• Persistent respiratory tract infections

(Mycoplasma or Chlamydophilia pneumonia)• Psychological diseases esp. depression

Bell MC, Busse WW.J Allergy Clin Immunol: In Practice 2013;1:110-21

Page 38: Severe asthma

Expert Panel Report 3:Guidelines for the Diagnosis and and management of asthma

Page 39: Severe asthma

GINA Guideline 2011

Page 40: Severe asthma

Omalizumab (humanized monoclonal anti-IgE antibody)

Page 41: Severe asthma

• randomized, placebo-controlled, double-blind study

• 28-week treatment phase

• 419 pts (12–75 yr) inadequately controlled with high-dose ICS and LABA with reduced lung function

• omalizumab (209 pts) vs placebo (210 pts)

• Omalizumab dose of at least 0.016 mg/kg per IU/ml of IgE subcutaneously (based on the patient’s bodyweight and total serum IgE level ) was administered every 2 or 4 weeks

Humbert M, et al. Allergy 2005;60:309-16

Page 42: Severe asthma

Humbert M, et al. Allergy 2005;60:309-16

Page 43: Severe asthma

• Total emergency visits in the treated-group were reduced by 44% ( 0.24 vs 0.43, P = 0.038 )

• Clinically meaningful improvement asthma quality of life questionnaire (AQLQ) ( > 0.5-point from baseline) was observed in the treated-group as compared to placebo (60.8% vs 47.8%, p =0.008)

• Mean morning PEF significant greater for omalizumab than placebo ( P= 0.042)

• The FEV1 (% predicted) was significantly improved with omalizumab compared with placebo (difference = 2.8% predicted ( P=0.043))

Humbert M, et al. Allergy 2005;60:309-16

Page 44: Severe asthma

Safety and tolerability

similar in Omalizumab and Placebo Humbert M, et al. Allergy 2005;60:309-16

Page 45: Severe asthma

• pooled data from 7 studies• severe persistent asthma• 12-79 yrs

• 4308 patients (2511 omalizumab , 1797 control)

• omalizumab was added to current asthma therapy and – compared with placebo (in five double-blind studies) – or with current asthma therapy alone (in two open-label

studies)

Bousquet J, et al. Allergy 2005;60:302-8

Page 46: Severe asthma

Asthma exacerbations

Reduced asthma exacerbation 38% in omalizumab group

Bousquet J, et al. Allergy 2005;60:302-8

Page 47: Severe asthma

Emergency visits

Reduced ER visit 47 % in omalizumab groupBousquet J, et al. Allergy 2005;60:302-8

Page 48: Severe asthma

Relative rates of asthma exacerbations across subgroupsin pooled studies

Point estimates and 95% confidence intervals for asthma exacerbation rate ratio (omalizumab : control)

Bousquet J, et al. Allergy 2005;60:302-8

Improvement with omalizumab was seen regardless of age, sex, baseline FEV1, baseline serum IgE, dosind schedule

Page 49: Severe asthma

Other treatment

Pharmacologic• Anti IL-5 : Mepolizumab, Reslizumab• Anti IL-13 : Anrukinzumab , Lebrikizumab• Anti IL-4 : Pascolizumab

Non-pharmacologic• Bronchial thermoplasty

Page 50: Severe asthma

• randomized, double-blind, placebo-controlled, parallel-group study

• 61 subjects who had refractory eosinophilic asthma and a history of recurrent severe exacerbations

• Mepolizumab (29 subjects) VS Placebo (32) at monthly intervals for 1 year– 750 mg Mepolizumab IV

Haldar P, et al.NEJM 2009;360:973-84

Inclusion criteria : -refractory asthma according to ATS criteria-sputum eosinophil > 3% on at least one occasion in previous 2 years despite high-dose corticosteroid treatment-at least two exacerbations requiring rescue prednisolone in previous 12 months

Page 51: Severe asthma

Age 21-72 yr

Haldar P, et al.NEJM 2009;360:973-84

Page 52: Severe asthma

The mean number of exacerbations : 2.0 in mepolizumab group VS 3.4 in placebo group (relative risk, 0.57; 95% CI , 0.32 to 0.92; P = 0.02).

Haldar P, et al.NEJM 2009;360:973-84

Page 53: Severe asthma

Haldar P, et al.NEJM 2009;360:973-84

Page 54: Severe asthma

Haldar P, et al.NEJM 2009;360:973-84

Page 55: Severe asthma

Haldar P, et al.NEJM 2009;360:973-84

Safety

acceptable adverse- event and side-effect profile

Page 56: Severe asthma

Conclusion

Mepolizumab • significantly fewer severe exacerbations • Significant improvement in the score on the AQLQ • significantly lowered eosinophil counts in the blood

and sputum• There were no significant differences between the

groups with respect to symptoms, FEV1 after bronchodilator use, or airway hyperresponsiveness

• The only serious adverse events reported were hospitalizations for acute severe asthma

Haldar P, et al.NEJM 2009;360:973-84

Page 57: Severe asthma

• Anti-IL-5 therapy may not provide benefit to all patients with severe asthma

• It does appear to have a therapeutic potential to reduce exacerbations in subgroups with severe eosinophilic disease

Page 58: Severe asthma

• monoclonal antibody to IL-13• randomized, double-blind, placebo-controlled

study

• 219 adults who had asthma that was inadequately controlled despite inhaled glucocorticoid therapy

Corren J,et al. NEJM 2011;365:1088-98

Page 59: Severe asthma

Corren J,et al. NEJM 2011;365:1088-98

Page 60: Severe asthma

Corren J,et al. NEJM 2011;365:1088-98

Page 61: Severe asthma

Corren J,et al. NEJM 2011;365:1088-98

At week 12

P = 0.02

P = 0.03

P = 0.61

Relative changes in FEV1 were evident after 1 week of treatment and were sustained throughout the study

Page 62: Severe asthma

Corren J,et al. NEJM 2011;365:1088-98

Page 63: Severe asthma

P=0.045

Corren J,et al. NEJM 2011;365:1088-98

Page 64: Severe asthma

Conclusion• Treatment with lebrikizumab was associated

with a significant improvement in pre-bronchodilator FEV1

• No significant reductions in exacerbations rate and asthma symptoms

• Prespecified marker, serum periostin, could potentially be used to identify patients with asthma who may have an increased response to lebrikizumab treatment

• This finding requires replication

Corren J,et al. NEJM 2011;365:1088-98

Page 65: Severe asthma

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 66: Severe asthma

• Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial

• 30 investigational sites in six countries• randomized (2:1)

• 288 adult subjects (18–65 years of age)• randomized to BT or sham control underwent

three bronchoscopy procedures

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 67: Severe asthma

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 68: Severe asthma

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 69: Severe asthma

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 70: Severe asthma

*Posterior probability of superiority = 95.5%. †Posterior probability of superiority = 99.9%.

Castro M,et al. Am J Respir Crit Care Med 2010;181:116-24.

Page 71: Severe asthma

JACI.2013, Aug 30

Page 72: Severe asthma

• The proportion of subjects having severe exacerbations in each subsequent year (years 2, 3, 4, and 5) compared with the first year after BT were not significantly different

• The decrease in severe exacerbation rates that was achieved in the posttreatment period after BT in year 1 was maintained out to 5 years

JACI.2013, Aug 30

Page 73: Severe asthma

• The decrease in rates of ED visits that was achieved after BT in year 1 was maintained out to 5 years

JACI.2013, Aug 30

Page 74: Severe asthma

JACI.2013, Aug 30

Page 75: Severe asthma

• BT is an effective and safe therapy

• A single BT treatment comprising 3 procedures provides long-term benefit to at least 5 years

• Whether BT is a disease modifying therapy will depend on the results of future appropriately designed clinical studies

JACI.2013, Aug 30

Page 76: Severe asthma

Bell MC, Busse WW.J Allergy Clin Immunol: In Practice 2013;1:110-21

Personalized treatment

Page 77: Severe asthma

Take home message

• Severe asthma : Persons who require primarily large doses of ICSs in attempts to achieve disease control

• Because treatment non adherence is common at all levels of asthma severity always needs to be considered before concluding that a medication is not effective

• Accurate diagnosis (need PEF or spirometry)• Assessment and control of comorbidities

Page 78: Severe asthma

Take home message

• Severe asthma is a protean disease

• A better understanding of the different phenotypic variants may allow for not only greater understanding of the disease but also direction for improved treatment strategies

Page 79: Severe asthma